Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection of Cryptococcus neojormans fungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent.

##STR00001##

Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.

The invention provides a liquid crystal compound satisfying at least one of physical properties such as a high stability to heat or light, a high clearing point (or a high maximum temperature), a low minimum temperature of a liquid crystal phase, a small viscosity, a suitable optical anisotropy, a small dielectric anisotropy, a suitable elastic constant and a good compatibility with other liquid crystal compounds, a liquid crystal composition including this compound, and a liquid crystal display device containing this composition. The invention provides a compound represented by formula (1): ##STR00001##
where R.sup.1 and R.sup.2 is alkyl having 1 to 20 carbons or the like; one of L.sup.1 and L.sup.2 is both hydrogens, and the other is both fluorines; Z.sup.1 and Z.sup.2 are independently a single bond, COO, OCO, OCH.sub.2, CH.sub.2O, CF.sub.2O, OCF.sub.2, CH.sub.2CH.sub.2, CHCH, CC or the like.

An object of the present invention is to provide a method for producing an ether compound easily in a small number of steps at lower costs in high yields. The present invention relates to a method in which the ether compound represented by the general formula (1) is produced by reacting the specific carbonyl compound specified in the general formula (2) and the specific dialkoxy compound specified in the general formula (3) with hydrogen in the presence of a hydrogenation catalyst and an acidic substance to perform hydrogenation. ##STR00001##

The energy is minimized that is required to lower the concentration of the high boiling point components (containing the poisoning substance for the dehydrogenation catalyst) contained in the hydrogenated aromatic compound produced by the hydrogenation of an aromatic compound. The hydrogenation system (2) for an aromatic compound comprises a hydrogenation reaction unit (11) for adding hydrogen to an aromatic compound by a hydrogenation reaction to produce a hydrogenated aromatic compound, a first separation unit (12) for separating a gas and a liquid component from a product of the hydrogenation reaction unit while maintaining a temperature of the product generally higher than a boiling point of the hydrogenated aromatic compound, and a second separation unit (13) for separating the hydrogenated aromatic compound from the gas component separated by the first separation unit.

The invention relates to a novel process for the synthesis and/or purification of tetrahydrocannabinolic acid (THCA) alkanoates and/or cannabidiolic acid (CBDA) di-alkanoates. The invention also provides novel derivatives of CBDA di-alkanoates and THCA alkanoates according to Formula I, wherein R.sup.1=methyl-4-(prop-1-en-2-yl)-cyclohex-1-ene-3-yl (limonenyl); wherein R.sup.2=acetate, propionate, butyrate, or OH; wherein R.sup.3=propyl, pentyl, or heptyl; wherein R.sup.4=methyl, ethyl, or propyl; wherein R.sup.5=methyl, ethyl, or propyl, or wherein R.sup.1=methyl-4-(2-propyl)cyclohex-1-ene-3-yl or methyl-4-(2-propyl)-cyclohex-5-ene-3-yl, wherein R.sup.2O, and R.sup.1 and R.sup.2 together form a ring structure in which R.sup.2 is an internal ring atom, wherein R.sup.3=propyl, pentyl, or heptyl, wherein R.sup.4=methyl, ethyl, or propyl, and wherein R.sup.5=methyl, ethyl, or propyl, or wherein R.sup.1=methyl-4-(2-propyl)-cyclohex-1-ene-3-yl, wherein R.sup.2O, and R.sup.1 and R.sup.2 together form a ring structure in which R.sup.2 is an internal ring atom, wherein R.sup.3=propyl, pentyl, or heptyl, wherein R.sup.4 and R.sup.5 vanish, i.e. are radicals forming a direct bond to each other.

The energy is minimized that is required to lower the concentration of the high boiling point components (containing the poisoning substance for the dehydrogenation catalyst) contained in the hydrogenated aromatic compound produced by the hydrogenation of an aromatic compound. The hydrogenation system (2) for an aromatic compound comprises a hydrogenation reaction unit (11) for adding hydrogen to an aromatic compound by a hydrogenation reaction to produce a hydrogenated aromatic compound, a first separation unit (12) for separating a gas and a liquid component from a product of the hydrogenation reaction unit while maintaining a temperature of the product generally higher than a boiling point of the hydrogenated aromatic compound, and a second separation unit (13) for separating the hydrogenated aromatic compound from the gas component separated by the first separation unit.

Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.